At AACR, Foundation Medicine Reports Strong Demand for NGS-based Profiling to Guide Cancer Treatment | GenomeWeb

By Bernadette Toner

CHICAGO – A few months ahead of the commercial launch of its genomic profiling test for clinical oncology, Foundation Medicine is receiving around 25 patient samples a week from physicians seeking to use its next-gen sequencing-based approach to inform cancer treatment, a company official said this week at the annual meeting of the American Association for Cancer Research.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.